Hopetoretire, you make some good points.Sometimes, what should be is not what happens, but there is potential for Afrezza to take a good slice of the non-insulin market for type 2 patients.If that happens, then it is a bonus.Even without the potential to exceed Humalog's revenue, Mannkind seems to have significant value.I am trying to be conservative, so that there is a margin of safety in my estimates.

I read an interesting article in the NY Times this morning about “Comparative effectiveness” studies.

Why Studies That Compare Treatments Lack Impact

http://well.blogs.nytimes.com/2012/11/08/why-studies-that-compare-treatments-lack-impact/?ref=health